Alvotech Shares Rebound 20% After FDA Letter Selloff
03 7월 2023 - 10:37PM
Dow Jones News
By Dean Seal
Shares of Alvotech have rebounded on Monday from a minor selloff
last week following the company's disclosure that approval for its
drug candidate AVT02 would likely be delayed in the U.S.
The stock is up 20% at $9.30 in premarket trading. At Friday's
close, shares had fallen 22% since the start of the year.
The Icelandic company said Wednesday that it had received a
complete response letter from the U.S. Food and Drug Administration
for a second biologics license application it submitted for AVT02,
a biosimilar candidate to Abbvie's Humira.
Because approval is likely to be delayed, Alvotech said it would
explore options to raise additional capital to continue advancing
pipeline development in the near-term.
Shares sank by more than 8% the next day but recovered on Friday
to close at $7.74.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
July 03, 2023 09:22 ET (13:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Alvontech (NASDAQ:ALVO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Alvontech (NASDAQ:ALVO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024